13/07/2025
Advances in Medical research. Path to the future.
I Love Medical Profession
A groundbreaking treatment using the herpes virus may soon be cleared to fight one of the deadliest skin cancers.
A genetically engineered herpes virus called RP1 could soon be approved by the U.S. Food and Drug Administration to treat advanced melanoma, one of the deadliest forms of skin cancer.
In a clinical trial involving 140 patients whose cancers were unresponsive to standard therapies, RP1—used in combination with the immunotherapy drug nivolumab—shrank tumors in 30% of participants.
Remarkably, in half of those cases, all detectable tumors disappeared. Unlike its predecessor, T-VEC, which is only approved for superficial skin tumors, RP1 can be injected into deeper tumors and is designed to fuse cancer cells together, boosting immune attack on the disease throughout the body.
This potential approval would mark only the second time a virus-based cancer therapy gains regulatory approval in the U.S. and Europe. It represents a leap forward in the century-old idea of using viruses to treat cancer—an approach historically fraught with safety concerns. By targeting tumors directly and stimulating the immune system to fight cancer cells more broadly, RP1 exemplifies a new wave of cancer therapies that could revolutionize treatment for patients with few other options. With a decision from the FDA expected by the end of July, scientists and patients alike are eagerly watching what could be a turning point in cancer care.
source:
Findings from the analysis were presented at the 2025 ASCO Annual Meeting,